A phase I first-in-human study of REGN910 (SAR307746), a fully human and selective angiopoietin-2 (Ang2) monoclonal antibody (MAb), in patients with advanced solid tumor malignancies.

被引：0
|
作者：
Papadopoulos, Kyriakos P.
Sahebjam, Solmaz
Kelley, Robin Katie
Tolcher, Anthony W.
Razak, Albiruni R. A.
Patnaik, Amita
Bedard, Philippe L.
Arcos, Rebecca
Adriaens, Lieve
Brownstein, Carrie M.
Lowy, Israel
Gao, Bo
DiCioccio, A. Thomas
Trail, Pamela
Siu, Lillian L.
机构：
[1] START Ctr Canc Care, San Antonio, TX USA
[2] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[3] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
[4] South Texas Accelerated Res Therapeut LLC, San Antonio, TX USA
[5] Univ Toronto, Dept Med, Div Med Oncol & Hematol, Princess Margaret Canc Ctr,Univ Hlth Network, Toronto, ON, Canada
[6] Regeneron Pharmaceut Inc, Tarrytown, NY USA
[7] Princess Margaret Canc Ctr, Toronto, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2517
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Phase I, first-in-human, open-label, dose-escalation study of U3-1565, a fully human anti-HB-EGF monoclonal antibody, in patients with advanced solid tumors.
    Moore, Kathleen N.
    Bendell, Johanna C.
    Olszanski, Anthony J.
    Desai, Madhuri
    Jansen, Mendel
    Scheyer, Richard David
    Senaldi, Giorgio
    LoRusso, Patricia
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [42] Phase I first-in-human study of HLX07, a novel and improved recombinant anti-EGFR humanized monoclonal antibody, in patients with advanced solid cancers
    Hou, Ming-Mo
    Ho, Ching-Liang
    Lin, Hsuan-Yu
    Zhu, Yunting
    Zhang, Xiaodi
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (05) : 1315 - 1323
  • [43] HGS-ETR2 - A fully human monoclonal antibody to TRAIL-R2: Results of a phase I trial in patients with advanced solid tumors.
    Patnaik, A.
    Wakelee, H.
    Mita, M.
    Fitzgerald, A.
    Hill, M.
    Fox, N.
    Howard, T.
    Ullrich, S.
    Tolcher, A.
    Sikic, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 123S - 123S
  • [44] A first-in-human phase I dose escalation of YH001, an anti-CTLA-4 monoclonal antibody (mAb) in combination with toripalimab (anti-PD-1 mAb) in patients with advanced solid tumors.
    Ganju, Vinod
    Cooper, Adam
    Gao, Bo
    Wilkinson, Kate
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [45] First-in-human phase I trial of BI 836880, a vascular endothelial growth factor (VEGF)/angiopoietin-2 (Ang-2)-blocking nanobody, given every 3 weeks (q3w) in patients (pts) with advanced/metastatic solid tumors.
    Le Tourneau, Christophe
    Claus, Rainer
    Ricci, Francesco
    Hackanson, Bjorn
    Rummelt, Christoph
    Fietz, Oliver
    Arnhold, Thomas
    Roy, Dooti
    Oum'Hamed, Zohra
    Fritsch, Ralph M.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [46] A first-in-human, phase I, dose-escalation study to evaluate pharmacokinetics, safety, and tolerability of KD6001, a novel anti-CTLA-4 monoclonal antibody (mAb) in patients with advanced solid tumors
    Tang, Bixia
    Duan, Rong
    Li, Siming
    Sheng, Xinan
    Si, Lu
    Cui, Chuanliang
    Mao, Lili
    Wang, Xuan
    Lian, Bin
    Wei, Xiaoting
    Yan, Xieqiao
    Li, Juan
    Zhou, Li
    Xu, Huayan
    Li, Caili
    Cai, Zeling
    Zhang, Chi
    Wang, Fangfang
    Guo, Jun
    Chi, Zhihong
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [47] First-in-human Phase I study of M4112, the first dual inhibitor of indoleamine 2,3-dioxygenase-1 and tryptophan 2,3-dioxygenase 2, in patients with advanced solid malignancies
    Papadopoulos, Kyriakos
    Eder, Paul
    Piha-Paul, Sarina A.
    Gimmi, Claude
    Hussey, Elizabeth
    Zhang, Sen
    Li, Lu
    Habermehl, Christina
    Naing, Aung
    CANCER RESEARCH, 2019, 79 (13)
  • [48] A phase I, multicenter, open-label, first-in-human study to evaluate MEDI0680, an anti-programmed cell death-1 antibody, in patients with advanced malignancies.
    Infante, Jeffrey R.
    Goel, Sanjay
    Tavakkoli, Fatemeh
    Marshall, Shannon
    Robbins, Paul B.
    D'Angelo, Gina
    Gribbin, Matthew Joseph
    Karakunnel, Joyson Joseph
    Naing, Aung
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [49] First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies
    Munster, Pamela
    Aggarwal, Rahul
    Hong, David
    Schellens, Jan H. M.
    van der Noll, Ruud
    Specht, Jennifer
    Witteveen, Petronella O.
    Werner, Theresa L.
    Dees, E. Claire
    Bergsland, Emily
    Agarwal, Neeraj
    Kleha, Joseph F.
    Durante, Michael
    Adams, Laurel
    Smith, Deborah A.
    Lampkin, Thomas A.
    Morris, Shannon R.
    Kurzrock, Razelle
    CLINICAL CANCER RESEARCH, 2016, 22 (08) : 1932 - 1939
  • [50] First-in-human, multicenter, open-label, phase I study of ATOR-1017 (evunzekibart), a 4-1BB antibody, in patients with advanced solid malignancies
    Carneiro, Ana
    Hahn, Amanda
    Ellmark, Peter
    Enell Smith, Karin
    Schultz, Lena
    Ambarkhane, Sumeet
    Yachnin, Jeffrey
    Ullenhag, Gustav J.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2025, 13 (01)
12345